Evidence map›Paper›PMID 28598898›Full record

ArticleNuclear medicine communications2017

A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.

Saima Nawaz, Gregory E D Mullen, Philip J Blower, James R Ballinger

Open access · hybridAbstract read
In one paragraph

Article in Nuclear medicine communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Optimal His-Tag Design for Efficient [Bioconjugate chemistry · 2021
    Article
  4. Article
  5. QuantitativeBioconjugate chemistry · 2020
    Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Saima NawazaDivision of Imaging Sciences and Biomedical Engineering, King's College London bDepartment of Nuclear Medicine, Guy's and St Thomas' Hospital, London, UK.
Gregory E D Mullen
Philip J Blower
James R Ballinger
King's College London · GBSt Thomas' Hospital · GB

Funding

Cancer Research UK 16463Wellcome Trust
6 · The paper itself

Abstract

introductionProstate-specific membrane antigen (PSMA) is an extensively studied antigen for imaging prostate cancer. We prepared a single-chain variable fragment (scFv) of J591, a monoclonal antibody that recognises an external epitope of PSMA, incorporating a His-tag for labelling with Tc tricarbonyl, and evaluated its binding using human PCa cell lines.

methodsJ591(scFv) was expressed in HEK-293T cells and purified by metal ion affinity chromatography, followed by size exclusion chromatography. Stability and monomer/dimer ratios of purified scFv under different storage conditions were analysed by SDS-PAGE and analytical size exclusion chromatography. J591(scFv) was labelled with (Equation is included in full-text article.)at 37°C for 60 min. The stability of Tc-scFv in human serum was analysed by SDS-PAGE with autoradiography. Cell-binding studies were carried out using PC3LN3 (PSMA negative) and PC3LN3-PSMA (a variant engineered to express PSMA) cell lines.

resultsJ591(scFv) was most stable to dimerisation on storage at -80°C compared with -20 and 4°C. Radiochemical yields of 85-90% were obtained with the final radiochemical purity of more than 99% after purification by gel filtration. In these small-scale studies, the maximum specific activity achieved was 7 MBq/μg. Liquid chromatography-mass spectrometry showed the formation of Tc-J591(scFv), which was radiochemically stable in serum, with no dissociation of Tc over 24 h. Cell-binding assays showed specific binding to PSMA-positive cells.

conclusionJ591(scFv) can be radiolabelled with (Equation is included in full-text article.)conveniently and efficiently. The labelled product was stable in serum. It showed selective binding to PSMA-positive cells compared with PSMA-negative cells. This potential radiotracer warrants evaluation in PCa xenograft models.

Indexed as

Antigens, SurfaceCell Line, TumorGene Expression Regulation, NeoplasticGlutamate Carboxypeptidase IIHEK293 CellsHumansIsotope LabelingMaleProstatic NeoplasmsRadiochemistrySingle-Chain AntibodiesTechnetiumAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IISingle-Chain AntibodiesTechnetium

Identifiers

PMID28598898
PMCPMC5508854
OpenAlexW2621489168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.